Repligen (NASDAQ:RGEN) issued an update on its FY19 earnings guidance on Thursday morning. The company provided EPS guidance of $0.94-0.98 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.96. The company issued revenue guidance of $264-268 million, compared to the consensus revenue estimate of $255.79 million.
RGEN traded up $0.60 on Thursday, hitting $94.99. 27,477 shares of the company’s stock were exchanged, compared to its average volume of 542,339. The firm has a market capitalization of $4.49 billion, a price-to-earnings ratio of 130.12, a PEG ratio of 5.63 and a beta of 1.10. Repligen has a twelve month low of $45.00 and a twelve month high of $96.25. The company’s fifty day simple moving average is $85.06. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03.
Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.02. The firm had revenue of $60.63 million for the quarter, compared to analyst estimates of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. Repligen’s quarterly revenue was up 35.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 earnings per share. On average, equities analysts expect that Repligen will post 0.96 EPS for the current fiscal year.
In other Repligen news, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $77.35, for a total value of $100,168.25. Following the sale, the director now owns 118,329 shares in the company, valued at $9,152,748.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Glenn L. Md Cooper sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the sale, the director now owns 35,975 shares in the company, valued at approximately $2,408,166.50. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Article: Why investors pay attention to retained earnings
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.